Insider Buying: Mesa Laboratories (NASDAQ:MLAB) Director Acquires 1,301 Shares of Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) Director Mark Christopher Capone bought 1,301 shares of Mesa Laboratories stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average cost of $76.35 per share, with a total value of $99,331.35. Following the transaction, the director owned 3,429 shares of the company’s stock, valued at $261,804.15. This trade represents a 61.14% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mesa Laboratories Stock Performance

NASDAQ:MLAB traded down $14.46 during mid-day trading on Tuesday, reaching $73.23. 300,970 shares of the company’s stock were exchanged, compared to its average volume of 101,781. Mesa Laboratories, Inc. has a one year low of $55.45 and a one year high of $131.20. The company has a debt-to-equity ratio of 0.86, a quick ratio of 1.45 and a current ratio of 1.94. The business’s fifty day simple moving average is $87.46 and its two-hundred day simple moving average is $78.20. The firm has a market capitalization of $404.23 million, a PE ratio of 114.42 and a beta of 0.85.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings data on Tuesday, February 3rd. The medical instruments supplier reported $3.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.41 by $0.66. Mesa Laboratories had a net margin of 1.51% and a return on equity of 22.02%. The firm had revenue of $65.13 million during the quarter, compared to the consensus estimate of $63.23 million. Analysts anticipate that Mesa Laboratories, Inc. will post 8 earnings per share for the current fiscal year.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Investors of record on Saturday, February 28th will be given a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $0.64 dividend on an annualized basis and a yield of 0.9%. Mesa Laboratories’s dividend payout ratio is currently 100.00%.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Mesa Laboratories in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 7th. Zacks Research raised shares of Mesa Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. Finally, Wells Fargo & Company upped their price target on shares of Mesa Laboratories from $83.00 to $94.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 4th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $94.00.

Institutional Trading of Mesa Laboratories

Several institutional investors and hedge funds have recently modified their holdings of MLAB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Mesa Laboratories by 4.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock valued at $364,000 after acquiring an additional 143 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Mesa Laboratories by 5.5% in the 2nd quarter. Franklin Resources Inc. now owns 3,476 shares of the medical instruments supplier’s stock worth $328,000 after purchasing an additional 182 shares during the period. American Century Companies Inc. boosted its stake in shares of Mesa Laboratories by 1.5% in the 2nd quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock valued at $1,265,000 after purchasing an additional 194 shares during the last quarter. CWM LLC increased its position in shares of Mesa Laboratories by 48.9% during the third quarter. CWM LLC now owns 597 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 196 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in Mesa Laboratories by 30.9% during the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock worth $69,000 after buying an additional 243 shares during the last quarter. 90.60% of the stock is currently owned by institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.